Improving CAR-T cell therapy using advanced gene editing techniques
Non-viral genome, epigenome, and transcriptome engineering for clinical CAR-T cell manufacturing
['FUNDING_CAREER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10909062
This study is working on new ways to improve cancer treatments by using a special technology to make T cells better at fighting cancer, so patients can have safer and more personalized therapies.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10909062 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative methods to engineer T cells for cancer treatment using CRISPR technology. It aims to enhance the precision and safety of CAR-T cell therapies by exploring non-viral techniques for modifying the genome, epigenome, and transcriptome of T cells. The project will also establish processes that comply with Good Manufacturing Practices to ensure these therapies can be safely produced for clinical use. Patients may benefit from more effective and personalized cancer treatments as a result of this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that may be treated with CAR-T cell therapies.
Not a fit: Patients who do not have cancers or who are not eligible for CAR-T cell therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective CAR-T cell therapies for cancer patients.
How similar studies have performed: Other research has shown promise in using CRISPR technology for gene editing in T cells, indicating a potential for success in this novel approach.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHY, BRIAN R — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: SHY, BRIAN R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.